IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection
IGC Pharma (NYSE American:IGC), a clinical-stage pharmaceutical company, has received its third award from the National Institute on Aging (NIA) for excellence in AI code development as part of the PREPARE Challenge. The company's AI team was recognized for developing well-structured and transparent code for Alzheimer's detection.
The team created a multilingual AI model using DementiaBank data to detect acoustic biomarkers linked to early cognitive decline. The company's AI initiatives include MINT-AD, an advanced platform integrating multiple biomarkers for individualized Alzheimer's disease forecasting. Previously, IGC received the Disproportionate Impact Award, third place in Phase 1, and a prize for generalization in Phase 2 of the PREPARE Challenge.
IGC Pharma (NYSE American:IGC), azienda farmaceutica in fase clinica, ha ricevuto il terzo riconoscimento dal National Institute on Aging (NIA) per l'eccellenza nello sviluppo di codice AI nell'ambito della PREPARE Challenge. Il team AI è stato premiato per aver sviluppato codice ben strutturato e trasparente per la rilevazione dell'Alzheimer.
Il gruppo ha realizzato un modello AI multilingue utilizzando i dati di DementiaBank per individuare biomarcatori acustici associati ai primi segni di declino cognitivo. Le iniziative AI dell'azienda comprendono MINT-AD, una piattaforma avanzata che integra più biomarcatori per prevedere in modo personalizzato l'evoluzione dell'Alzheimer. In precedenza IGC aveva ottenuto il Disproportionate Impact Award, il terzo posto nella Fase 1 e un premio per la generalizzazione nella Fase 2 della PREPARE Challenge.
IGC Pharma (NYSE American:IGC), una compañía farmacéutica en fase clínica, ha recibido su tercer reconocimiento del National Institute on Aging (NIA) por la excelencia en el desarrollo de código de IA como parte del PREPARE Challenge. El equipo de IA fue destacado por crear código bien estructurado y transparente para la detección del Alzheimer.
El equipo desarrolló un modelo de IA multilingüe usando datos de DementiaBank para detectar biomarcadores acústicos relacionados con el deterioro cognitivo temprano. Las iniciativas de IA de la empresa incluyen MINT-AD, una plataforma avanzada que integra múltiples biomarcadores para predecir de forma individualizada la evolución del Alzheimer. Anteriormente, IGC recibió el Disproportionate Impact Award, el tercer lugar en la Fase 1 y un premio por generalización en la Fase 2 del PREPARE Challenge.
IGC Pharma (NYSE American:IGC)는 임상 단계 제약사로, PREPARE 챌린지의 일환으로 AI 코드 개발 우수성에 대해 National Institute on Aging(NIA)로부터 세 번째 상을 받았습니다. 회사의 AI 팀은 알츠하이머 감지를 위한 구조화되고 투명한 코드로 인정받았습니다.
팀은 DementiaBank 데이터를 활용해 초기 인지 저하와 연관된 음향 바이오마커를 탐지하는 다국어 AI 모델을 만들었습니다. 회사의 AI 프로젝트에는 여러 바이오마커를 통합해 개별화된 알츠하이머 예측을 제공하는 고급 플랫폼 MINT-AD가 포함됩니다. 이전에 IGC는 Disproportionate Impact Award, 1단계 3위, 2단계 일반화 부문 상을 수상한 바 있습니다.
IGC Pharma (NYSE American:IGC), entreprise pharmaceutique en phase clinique, a reçu sa troisième distinction du National Institute on Aging (NIA) pour l'excellence du développement de code IA dans le cadre du PREPARE Challenge. L'équipe IA a été récompensée pour avoir conçu un code bien structuré et transparent pour la détection de la maladie d'Alzheimer.
L'équipe a créé un modèle IA multilingue en utilisant les données DementiaBank pour détecter des biomarqueurs acoustiques liés au déclin cognitif précoce. Les initiatives IA de l'entreprise incluent MINT-AD, une plateforme avancée intégrant plusieurs biomarqueurs pour prévoir de manière individualisée l'évolution de l'Alzheimer. Auparavant, IGC avait reçu le Disproportionate Impact Award, la troisième place lors de la Phase 1 et un prix pour la généralisation lors de la Phase 2 du PREPARE Challenge.
IGC Pharma (NYSE American:IGC), ein pharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat vom National Institute on Aging (NIA) seine dritte Auszeichnung für hervorragende AI-Code-Entwicklung im Rahmen der PREPARE Challenge erhalten. Das AI-Team wurde für die Entwicklung von gut strukturiertem und transparentem Code zur Alzheimer-Erkennung gewürdigt.
Das Team entwickelte ein mehrsprachiges AI-Modell unter Verwendung von DementiaBank-Daten, um akustische Biomarker zu erkennen, die mit frühem kognitiven Abbau zusammenhängen. Zu den AI-Initiativen des Unternehmens gehört MINT-AD, eine fortschrittliche Plattform, die mehrere Biomarker integriert, um die Alzheimer-Entwicklung individuell vorherzusagen. Zuvor erhielt IGC den Disproportionate Impact Award, den dritten Platz in Phase 1 und einen Preis für Generalisierungsleistung in Phase 2 der PREPARE Challenge.
- Recognition from NIA validates IGC's AI development capabilities in Alzheimer's detection
- Development of scalable and reusable AI models enhances research collaboration potential
- AI tools support patient identification and stratification for IGC's pharmaceutical pipeline
- Multiple awards demonstrate consistent excellence in AI development for Alzheimer's research
- None.
Insights
IGC Pharma's AI recognition from NIA strengthens its Alzheimer's research credibility, potentially benefiting their drug development pipeline.
IGC Pharma has received a special award for excellence in clean code development from the National Institute on Aging (NIA) PREPARE Challenge, marking their third recognition in this program. This award specifically acknowledges their well-structured, transparent AI code that can be readily understood and reused by other researchers—an important achievement in scientific research where reproducibility and transparency are increasingly valued.
The company's AI platform uses public data from DementiaBank to train multilingual models capable of detecting subtle acoustic biomarkers linked to early cognitive decline. What makes this technologically significant is the focus on interpretable AI—models whose decision-making processes can be understood by humans—which addresses a critical challenge in healthcare AI adoption.
This recognition has strategic implications for IGC's business model. Their AI capabilities directly support their pharmaceutical pipeline by potentially improving patient identification and stratification for clinical trials of their Alzheimer's candidates: IGC-AD1, TGR-63, and IGC-M3. More efficient patient selection could accelerate trial timelines and potentially improve outcomes by ensuring treatments are tested in appropriate populations.
The company is also developing MINT-AD, an advanced platform integrating multiple data types to forecast individualized disease trajectories. Such platforms represent the emerging frontier of precision medicine in neurodegenerative disease, where treatment effectiveness often depends on timing and patient-specific factors.
This third award (following a Disproportionate Impact Award and third place overall in Phase 1, plus a generalization prize in Phase 2) establishes a pattern of external validation for IGC's AI capabilities, potentially distinguishing them in the competitive Alzheimer's therapeutic landscape.
POTOMAC, MD / ACCESS Newswire / September 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced that its Artificial Intelligence (AI) team has been recognized with a special award for excellence in clean code development as part of the National Institute on Aging (NIA) PREPARE Challenge.
The award highlights IGC Pharma's achievement in producing well-structured, transparent, and highly organized AI code that can be readily understood and reused by other researchers and developers. This distinction underscores the Company's commitment to not only advancing Alzheimer's detection but also contributing to the broader scientific community by ensuring that its work is accessible, interpretable, and reproducible.
By leveraging open data sources such as DementiaBank, a publicly available repository of speech and language samples from patients with dementia, the IGC team trained a multilingual, interpretable AI model capable of detecting subtle acoustic biomarkers linked to early cognitive decline. Their clean and modular codebase ensures that the models can be scaled, tested, and adapted for use in diverse populations and contexts.
"Receiving recognition for clean code development reflects our deep commitment to scientific rigor, transparency, and collaboration," said Ram Mukunda, CEO of IGC Pharma. "By making our AI work both powerful and reusable, we not only contribute to the broader Alzheimer's research community but also strengthen our own pharmaceutical pipeline. These AI tools are instrumental for identifying and stratifying patients as part of our precision medicine approach, which in turn supports a multi-faceted commercialization strategy for our Alzheimer's portfolio, including IGC-AD1, TGR-63, and IGC-M3. Together, our therapeutics and AI platforms create a differentiated path forward in addressing Alzheimer's disease."
In addition to this award, IGC Pharma's submission in the PREPARE Challenge received the Disproportionate Impact Award and third place overall in Phase 1, and a prize for generalization on Phase 2 (Model Arena - Acoustic Track).
IGC's AI roadmap also includes MINT-AD (Multimodal Interpretable Transformer for Alzheimer's Disease), an advanced platform integrating neuroimaging, cognitive, genomic, lifestyle, and digital biomarkers to forecast individualized trajectories and support precision medicine.
To learn more about IGC Pharma's recognized AI project and to watch the official PREPARE Challenge presentation, please visit: Link
For more information about DementiaBank, visit https://dementia.talkbank.org/
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What award did IGC Pharma receive from the National Institute on Aging in 2025?
How is IGC Pharma using AI technology for Alzheimer's research?
What is IGC Pharma's MINT-AD platform?
What other awards has IGC Pharma won in the PREPARE Challenge?
